• Determine the impact of pre-existing HIV-1 drug resistance on treatment outcome through Week 144 • Describe the HIV-1 drug resistance mutations that developed through Week 144 • Determine the frequency and order of mutation development using the fi rst failure samples for the EVG/COBI/FTC/TDF subjects with emergent resistance
• Determine the impact of pre-existing HIV-1 drug resistance on treatment outcome through Week 144 • Describe the HIV-1 drug resistance mutations that developed through Week 144 • Determine the frequency and order of mutation development using the fi rst failure samples for the EVG/COBI/FTC/TDF subjects with emergent resistance
• Screening Genotypic Analysis: Genotypic analyses of HIV-1 protease (PR) and reverse transcriptase (RT) were performed at screening (GeneSeq, Monogram Biosciences). Subjects with resistance to study drugs were excluded. 
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Subjects with pre-existing resistance to a study drug by the GeneSeq Assay for RT/PR were excluded Stratifi cation by HIV RNA (> / ≤100,000 c/mL) EVG/COBI/FTC/TDF: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate EFV/FTC/TDF: efavirenz/emtricitabine/tenofovir disoproxil fumarate ATV + RTV + FTC/TDF: atazanavir + ritonavir + emtricitabine/tenofovir disoproxil fumarate -If the IN GeneSeq or PhenoSense assays failed to amplify, the IN genotype was determined using the IN GenoSure assay (Labcorp). If genotypic or phenotypic resistance was detected, retrospective genotypic and phenotypic analyses of PR, RT, and IN were conducted on stored baseline samples.
• First Failure Resistance Analyses: Subjects from the EVG/COBI/FTC/TDF group with documented emergent resistance mutations were further analyzed. The fi rst failure analysis consisted of genotyping of samples from the fi rst time point of virologic failure with HIV-1 RNA ≥400 copies/mL. The PRIme assay (Monogram Biosciences) was the primary assay used, but GeneSeq IN and GenoSure MG were used in the case of an assay failure. a. Resistance Analysis Population: Subjects who experience either suboptimal virologic response (<1 log 10 below baseline at/after Week 8, confi rmed at next visit and ≥400 c/mL), virologic rebound (two consecutive visits with HIV-1 RNA either ≥400 c/mL after achieving HIV-1 RNA <50, or >1 log 10 increase from nadir), or had HIV-1 RNA ≥400 c/mL at Week 48, Week 96, Week 144, or their last visit. b. One subject had emergent M46M/L in protease. c. One subject had emergent I50I/L and one subject had emergent Q58E in protease. a. PhenoSense PR/RT or IN (Monogram Biosciences). Phenotype above the defi ned assay cutoffs are colored red (FC above the biological or lower clinical cut-off) or green (at or below the cut-off). ND= no data due to assay failure. b. A62V is a fi tness compensatory mutation for K65R and does not alter susceptibility to TFV (Svarovskaia et al., 2008, JAIDS 48:428-436) . c. Clonal sequencing of the HIV-1 from this subject showed linkage of M184V and E92Q on the same genome in 25 of 25 clones. d. No phenotypic data was available, but N155H was present and has reduced susceptibility to EVG and RAL. e. No phenotypic data was available, but the site-directed mutant virus containing T97A+G163R had 4.09-fold reduced susceptibility to EVG. f. No genotypic cross-resistance to DTG based on United States Prescribing Information-defi ned list of Q148 substitution plus ≥2 of L74I/M, E138A/D/K/T, G140A/S, Y143H/R, E157Q, G163E/K/Q/R/S, or G193E/R. 
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